You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

ERIS Lifesciences gains on anti-diabetes drug acquisition

Capital Market 

The scrip rose 2.85% to Rs 446.25 after it informed about the acquisition of the trademark for anti-diabetes novel drug Switzerland based Zomelis for $13 million.

The acquisition of the trademark from from Novartis AG is only for the Indian market, the company said in a exchange filing. The announcement was made post trading hours yesterday, 3 December 2019.

Eris Lifesciences will start selling the product from December 10 in the Indian market.

The company said that the acquired trademark has been used for marketing Vildagliptin formulations, an oral anti-diabetic drug that has been promoted in India for close to 10 years. The trademark along with its applicable associate marks presently enjoy sales on a moving annual total (MAT) basis of Rs.63.96 crore.

"One of the Indian patents pertaining to Vildagliptin, namely Patent No. 212815 of the Patent holder, shall expire in the month of December 2019. The assignment of Zomelis trademark, which enjoys aforementioned patent exclusivity, is expected to provide a head-start to Eris vis-vis other branded generic players after the scheduled expiry of the aforementioned patent", the company said.

Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the indian pharmaceutical market.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, December 04 2019. 09:25 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU